Cotton rat immune responses to virus-like particles containing the pre-fusion form of respiratory syncytial virus fusion protein

Journal of Translational Medicine

Volumn 13, Issue 1, 2015, Pages

  Cullen, Lori McGinnes ^a   Blanco, Jorge C G ^b   Morrison, Trudy G ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b Sigmovir Biosystems Inc   (United States)

Author keywords

Cotton rats; Fusion protein; Neutralizing antibody titers; Respiratory syncytial virus; Vaccine

Indexed keywords

HYBRID PROTEIN; IMMUNOGLOBULIN G; NEUTRALIZING ANTIBODY; RESPIRATORY SYNCYTIAL VIRUS FUSION PROTEIN; RESPIRATORY SYNCYTIAL VIRUS VACCINE; UNCLASSIFIED DRUG; VIRUS ANTIBODY; VIRUS FUSION PROTEIN; VIRUS LIKE PARTICLE VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BIOASSAY; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNE RESPONSE; INFECTION PREVENTION; NONHUMAN; PROTEIN EXPRESSION; PROTEIN STABILITY; RAT; RESPIRATORY SYNCYTIAL VIRUS INFECTION; VIRUS LIKE AGENT; VIRUS TRANSMISSION; ANIMAL; BIRD; BLOOD; CHLOROCEBUS AETHIOPS; COS CELL LINE; DISEASE MODEL; FIBROBLAST; HUMAN; HUMAN RESPIRATORY SYNCYTIAL VIRUS; IMMUNIZATION; IMMUNOLOGY; LUNG; MOLECULAR CLONING; MOUSE; PATHOLOGY; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN TERTIARY STRUCTURE; SIGMODONTINAE; SILVER STAINING; VERO CELL LINE; VIROLOGY;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; BIRDS; CERCOPITHECUS AETHIOPS; CLONING, MOLECULAR; COS CELLS; DISEASE MODELS, ANIMAL; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FIBROBLASTS; HUMANS; IMMUNIZATION; LUNG; MICE; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT FUSION PROTEINS; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUSES; SIGMODONTINAE; SILVER STAINING; VACCINES, VIRUS-LIKE PARTICLE; VERO CELLS;

EID: 84946399224     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/s12967-015-0705-8     Document Type: Article

References (54)

1. Nair H, Nokes DJ, Gessner BD, Dherani M, Madhi SA, Singleton RJ, et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet. 2010;375(9725):1545-55.
2. Han LL, Alexander JP, Anderson LJ. Respiratory syncytial virus pneumonia among the elderly: an assessment of disease burden. J Infect Dis. 1999;179:25-30.
3. Falsey AR, Hennessey PA, Formica MA, Cox C, Walsh EE. Respiratory syncytial virus infection in elderly and high-risk adults. N Engl J Med. 2005;352:1749-59.
4. Falsey AR, Walsh EE. Respiratory syncytial virus infection in adults. Clin Microbiol Rev. 2000;13:371-84.
5. Raboni SM, Nogueira MB, Tsuchiya LR, Takahashi GA, Pereira LA, Pasquini R. Respiratory tract viral infections in bone marrow transplant patients. Transplant. 2003;76:142-6.
6. Walsh EE, Falsey AR, Hennessey PA. Respiratory syncytial and other virus infections in persons with chronic cardiopulmonary disease. Am J Respir Crit Care Med. 1999;160:791-5.
7. Hall CB. Respiratory syncytial virus and parainfluenza virus. N Engl J Med. 2001;344:1917-28.
8. Hall CB, Long CE, Schnabel KD. Respiratory syncytial virus infections in previously healthy working adults. Clin Infect Dis. 2001;33:792-6.
9. Power UF. Respiratory syncytial virus (RSV) vaccines-Two steps back for one leap forward. J Clin Virol. 2008;41:38-44.
10. Morrison TG, Walsh EE. Subunit and Virus-like Particle Vaccine Approached for Respiratory Syncytial Virus. In: Anderson LJ, Graham BS, editors. Challenges and opportunities for respiratory syncytial virus vaccines. Heidelberg, Berlin: Springer; 2013. p. 285-306.
11. Jardetsky TS, Lamb RA. A class act. Nature. 2004;427:307-8.
12. Smith EC, Popa A, Chang A, Masante C, Dutch RE. Viral entry mechanisms: the increasing diversity of paramyxovirus entry. FEBS J. 2009;276(24):7217-27. doi: 10.1111/j.1742-4658.2009.07401.x.
13. Lamb RA, Parks GD. Paramyxoviridae: the viruses and their replication. In: Knipe DM, Howley PM, Griffin DE, Lamb RA, Martin MA, Roizman B et al., editors. Fields Virology. Fifth Edition ed. Philadelphia: Lippincott Williams &Wilkins. 2007;1450-96.
14. Yin H-S, Paterson RG, Wen X, Lamb RA, Jardetzky TS. Structure of the uncleaved ectodomain of the paramyxovirus (hPIV3) fusion protein. Proc Natl Acad Sci USA. 2005;102:9288-93.
15. Yin H-S, Wen X, Paterson RG, Lamb RA, Jardetzky TS. Structure of the parainfluenza virus 5 F protein in its metastable, prefusion conformation. Nature. 2006;439:38-44.
16. Swanson KA, Settembre EC, Shaw CA, Dey AK, Rappuoli R, Mandl CW, et al. Structural basis for immunization with postfusion respiratory syncytial virus fusion F glycoprotein (RSV F) to elicit high neutralizing antibody titers. Proc Natl Acad Sci USA. 2011;108(23):9619-24. doi: 10.1073/pnas.1106536108.
17. McLellan JS, Yang Y, Graham BS, Kwong PD. Structure of respiratory syncytial virus fusion glycoprotein in the postfusion conformation reveals preservation of neutralizing epitopes. J Virol. 2011;85(15):7788-96. doi: 10.1128/jvi.00555-11.
18. McLellan JS, Chen M, Leung S, Graepel KW, Du X, Yang Y, et al. Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody. Science. 2013;340(6136):1113-7. doi: 10.1126/science.1234914.
19. Smith G, Raghunandan R, Wu Y, Liu Y, Massare M, Nathan M, et al. Respiratory syncytial virus fusion glycoprotein expressed in insect cells form protein nanoparticles that induce protective immunity in cotton rats. PLoS ONE. 2012;7(11):e50852. doi: 10.1371/journal.pone.0050852.
20. Magro M, Mas V, Chappell K, Vazquez M, Cano O, Luque D, et al. Neutralizing antibodies against the preactive form of respiratory syncytial virus fusion protein offer unique possibilities for clinical intervention. Proc Natl Acad Sci. 2012;109(8):3089-94. doi: 10.1073/pnas.1115941109.
21. McLellan JS, Chen M, Joyce MG, Sastry M, Stewart-Jones GBE, Yang Y, et al. Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus. Science. 2013;342(6158):592-8. doi: 10.1126/science.1243283.
22. McGinnes LW, Gravel KA, Finberg RW, Kurt-Jones EA, Massare MJ, Smith G, et al. Assembly and immunological properties of Newcastle disease virus-like particles containing the respiratory syncytial virus F and G proteins. J Virol. 2011;85:366-77. doi: 10.1128/jvi.01861-10.
23. Murawski MR, McGinnes LW, Finberg RW, Kurt-Jones EA, Massare M, Smith G, et al. Newcastle disease virus-like particles containing respiratory syncytial virus G protein induced protection in BALB/c mice with no evidence of immunopathology. J Virol. 2010;84:1110-23.
24. Jennings GT, Bachmann MF. The coming of age of virus-like particle vaccines. Biol Chem. 2008;389:521-36.
25. Noad R, Roy P. Virus-like particles as immunogens. Trends in Microbiol. 2003;11:438-44.
26. Bachmann MF, Jennings GT. Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. Nat Rev Immunol. 2010;10(11):787-96.
27. McGinnes-Cullen L, Schmidt MR, Kenward SA, Woodland RT, Morrison TG. Murine Immune Responses to Virus-Like Particle-Associated Pre- and Postfusion Forms of the Respiratory Syncytial Virus F Protein. J of Virol. 2015;89(13):6835-47.
28. Boukhvalova MS, Blanco J. The cotton rat Sigmondon Hispidus model of respiratory syncytial virus infection. In: Anderson LJ, Graham BS, editors. Challenges and Opportunities for Respiratory Syncytial Virus Vaccines. Berlin Heidelberg: Springer-Verlag; 2013.
29. Pantua HD, McGinnes LW, Peeples ME, Morrison TG. Requirements for the assembly and release of Newcastle disease virus-like particles. J Virol. 2006;80:11062-73.
30. Frank S, Kammerer RA, Mechling D, Schulthess T, Landwehr R, Bann J, et al. Stabilization of short collagen-like triple helices by protein engineering. J Mol Biol. 2001;308:1081-9.
31. Beeler JA, van Wyke Coelingh K. Neutralization epitopes of the F glycoprotein of respiratory syncytial virus: effect of mutation upon fusion function. J Virol. 1989;63(7):2941-50.
32. McGinnes LW, Morrison TG. Current Protocols in Microbiology., Newcastle Disease Virus-Like Particles: Preparation, Purification, Quantification, and Incorporation of Foreign GlycoproteinsUSA: Wiley; 2013.
33. Prince GA, Jenson AB, Horswood RL, Camargo E, Chanock RM. The pathogenesis of respiratory syncytial virus infection in cotton rats. Am J Path. 1978;93(3):771-91.
34. Prince GA, Curtis SJ, Yim KC, Porter DD. Vaccine-enhanced respiratory syncytial virus disease in cotton rats following immunization with Lot 100 or a newly prepared reference vaccine. J Gen Virol. 2001;82:2881-8.
35. McLellan JS, Chen M, Kim A, Yang Y, Graham BS, Kwong PD. Structural basis of respiratory syncytial virus neutralization by motavizumab. Nat Struct Mol Biol. 2010;17:248-50. doi: 10.1038/nsmb.1723.
36. Liljeroos L, Krzyzaniak MA, Helenius A, Butcher SJ. Architecture of respiratory syncytial virus revealed by electron cryotomography. Proc Natl Acad Sci. 2013;110(27):11133-8. doi: 10.1073/pnas.1309070110.
37. Piedra PA, Jewell AM, Cron SG, Atmar RL. Paul Glezen W. Correlates of immunity to respiratory syncytial virus (RSV) associated-hospitalization: establishment of minimum protective threshold levels of serum neutralizing antibodies. Vaccine. 2003;21(24):3479-82. doi: 10.1016/S0264-410X(03)00355-4.
38. Siber GR, Leombruno D, Leszczynski J, McIver J, Bodkin D, Gonin R, et al. Comparison of antibody concentrations and protective activity of respiratory syncytial virus immune globulin and conventional immune globulin. J Infect Dis. 1994;169(6):1368-73. doi: 10.1093/infdis/169.6.1368.
39. Prince GA, Hemming VG, Horswood RL, Chanock RM. Immunoprophylaxis and immunotherapy of respiratory syncytial virus infection in the cotton rat. Virus Res. 1985;3:193-206.
40. 2 components mediated reduced pulmonary inflammation in mice. J Gen Virol. 2009;90:1119-23.
41. Radu GU, Caidi H, Miao C, Tripp RA, Anderson LJ, Haynes LM. Prophylactic treatment with a G glycoprotein monoclonal antibody reduces pulmonary inflammation in RSV challenged naive and formalin-inactivated RSV immunized BALB/c mice. J Virol. 2010:JVI.00451-10. doi: 10.1128/jvi.00451-10.
42. Tripp RA, Dakhama A, Jones LP, Barskey A, Gelfand EW, Anderson LJ. The G glycoprotein of respiratory syncytial virus depresses respiratory rates through the CX3C motif and substance P. J Virol. 2003;77(11):6580-4. doi: 10.1128/jvi.77.11.6580-6584.2003.
43. Tripp RA. Pathogenesis of respiratory syncytial virus infection. Viral Immunol. 2004;17:165-81.
44. Tripp RA, Moore D, Jones L, Sullender WM, Winter J, Anderson LJ. Respiratory syncytial virus G and/or SH protein alters Th1 cytokines, natural killer cells, and neutrophils responding to pulmonary infection in BALB/c mice. J Virol. 1999;73:7099-107.
45. Boyoglu-Barnum S, Todd SO, Chirkova T, Barnum TR, Gaston KA, Haynes LM, et al. An anti-G protein monoclonal antibody treats RSV disease more effectively than an anti-F monoclonal antibody in BALB/c mice. Virology. 2015;483:117-25. doi: 10.1016/j.virol.2015.02.035.
46. Boyoglu-Barnum S, Chirkova T, Todd SO, Barnum TR, Gaston KA, Jorquera P, et al. Prophylaxis with a respiratory syncytial virus (RSV) anti-G protein monoclonal antibody shifts the adaptive immune response to RSV rA2-line19F infection from Th2 to Th1 in BALB/c mice. J Virol. 2014;88(18):10569-83. doi: 10.1128/jvi.01503-14.
47. Collins PL, Crowe JE. Respiratory syncytial virus and metapneumovirus. 5th ed. Fields Virology. Philadelphia: LippincottWilliams and Wilkins; 2007.
48. Littel-van den Hurk SD. Mapletoft JW, Arsic N, Kovacs-Nolan J. Immunopathology of RSV infection: prospects for developing vaccines without this complication. Rev Med Virol. 2007;17:5-34.
49. Openshaw PJ, Culley FJ, Olszewska W. Immunopathogenesis of vaccine-enhanced RSV disease. Vaccine. 2002;20(suppl 1):S27-31.
50. Openshaw PJ, Tregoning JS. Immune responses and disease enhancement during respiratory syncytial virus infection. Clin Microbiol Rev. 2005;18:541-55.
51. Schmidt MR, McGinnes-Cullen LW, Kenward SA, Willems KN, Woodland RT, Morrison TG. Modification of the respiratory syncytial virus F protein in virus-like particles impacts generation of B cell memory. J Virol. 2014;88(17):10165-76. doi: 10.1128/jvi.01250-14.
52. Connors M, Collins PL, Firestone C-Y, Sotnikov AV, Waitze A, Davis AR, et al. Cotton rats previously immunized with a chimeric RSV FG glycoprotein develop enhanced pulmonary pathology when infected with RSV, a phenomenon not encountered following immunization with vaccinia-RSV recombinants or RSV. Vaccine. 1992;10(7):475-84.
53. Delgado MF, Coviello S, Monsalvo AC, Melendi GA, Hernandez JZ, Batalle JP, et al. Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease. Nature Med. 2009;15:34-41.
54. Connors M. Pulmonary histopathology induced by respiratory synctial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB/c mice is abrogated by depletion of CD4+T cells. J Virol. 1992;66:7444-51.